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Dear Colleague,
The past year has seen major therapeutic
advances in gastroenterology and hepatology.
Two areas with notable gains are related to
infectious diseases: novel treatments directed
against recurrent Clostridium difficile infection
(CDI) and against the hepatitis C virus (HCV).
Clostridium difficile infection is an infectious
colitis with high associated morbidity and
mortality. Broad-spectrum antibiotics cause
CDI by depleting the normal colonic flora and
lowering barriers to C. difficile proliferation.
Antibiotics directed against C. difficile (i.e.,
metronidazole and oral vancomycin) have a
high initial success rate for CDI, but up to one-
third of patients experience recurrence.
Historically, recurrent CDI was treated with
extended, but often diminishingly effective
courses of oral vancomycin [1]. But beginning
in the 1980s, an alternative strategy was
pursued: feces from a healthy donor was given
via enema or colonoscopically to a diseased
individual. Called fecal microbiota
transplantation (FMT), this technique resulted
in durable cure rates over 95%, even among
patients with multiple recurrences [2]. But there
were problems with FMT. There was no
randomized data supporting it, and the testing
of donor stool for infectious microorganisms
was not standardized. This changed in January
2013 with the results of a randomized study of
oral vancomycin followed by FMT with pooled,
pre-screened stool versus vancomycin alone. In
this trial, 81% of the vancomycin–FMT group
versus 27% of the vancomycin alone group
experienced resolution of symptoms [3].
Subsequently, FMT has been expanded with
studies demonstrating that donor stool can be
collected, frozen, and administered later [4] or
even impregnated in gel capsules and taken by
mouth [5]. In the future, it is likely that specific
organisms, selected to compete for resources
against C. difficile, will replace FMT for
treatment of recurrent CDI.
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The hepatitis C virus is the most common
cause of liver failure requiring transplantation
in the developed world. Standard therapy for
chronic HCV is with pegylated interferon
alpha and ribavirin. Peginterferon must be
given via weekly injections and, in
combination with ribavirin, often has severe
side effects including fatigue, depression, and
anemia. Peginterferon–ribavirin given for
48 weeks has sustained virologic response
(SVR) rates of 40–50% for HCV genotype 1,
the most common viral genotype in the USA
[6]. In 2011, two new drugs were added to the
arsenal against HCV: the protease inhibitors
boceprevir and telaprevir. When combined
with peginterferon–ribavirin, protease
inhibitors improve SVR rates to 65–85%
among genotype 1 patients, even when
patients have previously responded to
peginterferon, but have relapsed [7, 8].
However, treatment with protease inhibitors
still requires peginterferon and is complicated
by severe side effects including treatment-
limiting anemia in up to 50% of patients. But
in 2013 interferon-free regimens emerged using
a new class of drugs, HCV polymerase
inhibitors [9, 10]. In one study, patients with
untreated HCV genotype 1 received an all-oral
regimen consisting of a protease inhibitor, a
polymerase inhibitor, and ribavirin and
achieved SVR rates of 52–69% after just
12 weeks of treatment [11]. Significant anemia
and other severe adverse events were rare
(\10%), suggesting that the regimen will be
appropriate for HCV genotype 1 patients who
cannot tolerate interferon. Several similar,
equally promising regimens are in phase 2 or
3 studies, so patients with HCV can expect to
have multiple all-oral treatment options.
The recent progress in CDI and HCV has
been encouraging and we expect further
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